Allstate Strategic Ventures Research
Investment Thesis
Allstate Strategic Ventures (ASV) is the corporate venture capital arm of The Allstate Corporation, founded in 2015 and headquartered alongside Allstate's corporate offices in Northbrook, Illinois. ASV makes venture capital investments in disruptive technology start-ups that can help shape the future of the insurance industry and adjacent markets. Its investments are explicitly designed to support Allstate's broader transformation strategy: broadening protection offerings for customers and introducing innovative technologies into Allstate's core businesses. ASV positions itself to portfolio founders as a "blue-chip anchor customer" that can help them validate use cases inside a Fortune 100 insurer and expedite a path to commercial engagement, in addition to providing capital.
Fund Structure
ASV operates through multiple internal fund vehicles with distinct mandates, overseen by Managing Director Tarik Galijasevic:
- Fund I focuses on Series A and later-stage investments in companies with near-term strategic value to Allstate, targeting commercial engagement with the startup within roughly 18 months of investment.
- Fund II invests from Seed stage onward, balancing strong financial returns with strategic alignment to the insurance industry and Allstate's roadmap.
- A third, longer-horizon fund focuses on emerging global trends in technology and insurance (including areas like climate risk and quantum computing), giving Allstate visibility into future disruption without expecting near-term commercial adoption.
Sector Focus
ASV's stated focus areas span insurtech, fintech, digital health, mobility models, the Internet of Things, the gig economy, cybersecurity, deep technology, and frontier technology. In practice, recent activity clusters around insurance distribution and enablement (Matic, an insurance brokerage marketplace), data infrastructure and analytics (Ocient), third-party risk and GRC software (VISO Trust), decisioning/AI infrastructure for financial services (Feathery), and gig-worker benefits technology (Stride Health, since acquired by Integrity).
Stage Focus
Blended across its fund structure, ASV invests from Seed through Series B and later, with Fund I skewing toward Series A+ and Fund II reaching down to Seed. Publicly documented rounds show ASV participating in Series A (Feathery), Series B and Series B extensions (Ocient, VISO Trust, Matic).
Check Size
Precise per-deal check sizes were not disclosed on ASV's own site or in secondary sources reviewed. Aggregator data references a $15M–$100M range, but that figure appears associated with Allstate's broader insurance-float investment program (Allstate Investments) rather than ASV's individual startup checks — actual round sizes ASV has participated in (e.g., Matic's $20M Series B extension, Ocient's $42.1M Series B extension tranche, Feathery's $30M Series A) suggest materially smaller per-firm allocations. This field should be treated as low-confidence until confirmed directly with ASV.
Lead Tendency
Across the investments reviewed, ASV consistently appears as a participating (non-lead) investor alongside other institutional and strategic VCs (e.g., Portage Ventures and Index Ventures led Feathery's round; NEA, Mastercard, and Venrock were among Stride Health's other backers). This is typical of corporate venture arms optimizing for strategic access rather than ownership/control, so ASV is classified as a "follows" investor with moderate confidence.
Recent Activity
ASV remains actively deploying as of mid-2026:
- July 2026: Participated in Feathery's $30M Series A (AI operating/decisioning system for financial services), alongside Portage Ventures, Index Ventures, Clocktower Ventures, Erie Strategic Ventures, and Bain Capital Ventures.
- April 2025: Contributed to Ocient's $42.1M Series B extension tranche (part of a $132M total Series B), alongside Blue Bear Capital, Solidigm, Massive, Zelkova, and Northwestern Mutual. ASV's Tarik Galijasevic publicly commented that Ocient's high-performance analytics approach was "a strong addition to the Allstate Strategic Ventures portfolio."
- November 2024: Participated in VISO Trust's $24M Series B (AI-powered third-party risk platform).
- 2023: Existing investor participating in Matic's $20M Series B extension (insurance brokerage/marketplace).
Two notable exits occurred in 2026: Stride Health, a portable-benefits enrollment platform for gig workers, was acquired by Integrity in July 2026; VISO Trust was acquired by Protecht Group in April 2026.
Portfolio Highlights
Known portfolio companies include Ocient (high-performance data analytics), VISO Trust (AI-powered third-party risk, exited to Protecht), Matic (insurance brokerage marketplace), Feathery (AI decisioning for financial services), Stride Health (gig-worker benefits, exited to Integrity), Inrupt (decentralized data/Solid protocol company), and Prevailion (cyber risk intelligence). This list is likely incomplete; ASV does not publish a full portfolio grid on its corporate page, and third-party trackers (PitchBook, CB Insights) gate most of the list behind subscriptions.
Team
- Tarik Galijasevic — Vice President & Managing Director, Head of the Corporate Venture Capital Group at Allstate Strategic Ventures. Previously at JPMorgan Chase and the Investment Banking Institute. Serves as ASV's primary public spokesperson on deal announcements.
- Josh Lumer — Senior Principal. Recognized as a Global Corporate Venturing "Rising Star" in 2022.
- Christopher (Chris) Quinn — Principal. Recognized as a Global Corporate Venturing "Rising Star" in 2024.
Additional team members (David Li, Spencer Singer, Mikey Kailis) were identified via LinkedIn/firm associations but their current specific titles could not be confirmed from public sources and are omitted here pending verification.
Decision Process
As a corporate venture arm with a segmented multi-fund structure (Fund I / Fund II / a longer-horizon strategic fund) reporting up through a Managing Director, ASV's investment decisions are best characterized as running through an internal investment committee process rather than a solo-GP or flat-partnership model, though this has not been independently confirmed.
Founder Preferences
Public materials do not detail explicit founder preferences. Given the strategic mandate, ASV likely favors founders building products with a credible path to commercial integration with Allstate's insurance, claims, mobility, or protection businesses, or founders building deep/frontier technology relevant to insurance risk over a longer horizon.
Geographic Focus
No explicit geographic mandate was found. All portfolio companies identified in this research are US-based, consistent with ASV's mandate to serve Allstate's primarily US insurance operations, though this is not a confirmed exclusive restriction.